{"entity":{"id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","aka":[],"tldr":"A phase 1/2 trial of MT218 injection in prostate cancer, run by Songqi Gao, now recruiting.","summary":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients is a phase 1/2 interventional study registered as NCT06262139 by Songqi Gao, with 12 participants planned, started 2024-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: MT218 injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06262139","url":"https://clinicaltrials.gov/study/NCT06262139"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06262139","phase":"1/2","setting":"An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients","sponsor":"Songqi Gao","participation":[{"nct":"NCT06262139","source":"https://clinicaltrials.gov/study/NCT06262139","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"8fea49d30838e4c95326d65b7d4a29d867df745b142678c27af48b5380d6704c","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-19","leadSponsor":"Songqi Gao","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":12,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2024-07-25","startedType":"actual","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06262139/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}